In this respect, T-Cell receptor therapy might be a more suitable alternative for uveal melanoma as this therapy aims for intracellular tissue differentiation antigens expressed via the major histocompatibility complex (MHC)-peptide, as for example gp100 or Melanoma antigen recognised by T-cells 1 (MART-1) which are highly expressed in uveal melanoma cells [18]. The gene discussed is PMEL; the disease is uveal melanoma.